Adds to existing law to establish provisions regarding limitation of distribution and waiver of immunity for certain human gene therapy products.
Summary
Senate Bill 1189 would add a new section to Idaho law restricting the distribution, sale, or administration of certain human gene therapy products used for infectious disease indications unless the manufacturer affirmatively waives immunity from suit for design-defect injuries. The bill specifically references immunity under the federal Vaccine Injury Compensation Program statute, 42 U.S.C. 300aa-1 et seq., and provides that if such a product is distributed, sold, or administered in Idaho, the manufacturer is deemed to have waived that immunity.
The bill defines “human gene therapy product” broadly to include products that act through transferred genetic material or by altering human genetic sequences, including nucleic acids, genetically modified microorganisms, engineered nucleases, and ex vivo genetically modified human cells. It also declares an emergency and would take effect on July 1, 2025.
Impact
If enacted, the bill would create a new condition on the availability of certain gene therapy products in Idaho, effectively tying market access to a manufacturer’s waiver of federal and other immunity protections for design-defect claims. It would add a new Section 39-4806 to Chapter 48, Title 39 of the Idaho Code and could affect manufacturers, distributors, healthcare providers, and patients by limiting access to covered products unless the waiver requirement is satisfied. The measure also intersects with federal vaccine-related immunity law by expressly referencing 42 U.S.C. 300aa-1 et seq.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available record. Based on the text alone, the bill appears to reflect a skeptical or restrictive approach toward certain gene therapy products, especially those used for infectious diseases, by prioritizing liability exposure over unrestricted distribution. The emergency clause suggests the sponsor viewed the issue as urgent.
Contention
The main point of contention is likely to be the bill’s requirement that manufacturers waive immunity as a condition of distribution, which could be viewed by supporters as improving accountability and by opponents as creating a barrier to access or conflicting with federal immunity frameworks. Another likely dispute is the bill’s broad definition of human gene therapy products, which could sweep in a wide range of technologies beyond traditional vaccines and raise concerns among biotechnology companies, healthcare providers, and public health advocates. Because no hearing transcript is available, the specific positions of legislators or stakeholders are not documented in the provided materials.